(Bloomberg) — Sarepta Therapeutics Inc.’s bulls may get some validation after the company’s experimental gene therapy for a rare type of muscular dystrophy improved physical fitness in a trio of patients.Updated data for the experimental compound showed patients with an inherited form of Limb-girdle muscular dystrophy reaped functional benefits in several areas after receiving SRP-9003, with a pair of teenagers posting gains in their ability to move when they typically would have experienced declines. Analysts had stressed that promising results could help the company shake-off a recent rout that wiped out $6 billion in market value as questions about the …read more
Source:: Yahoo Finance
